218 related articles for article (PubMed ID: 25070543)
1. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Bellera CA; Penel N; Ouali M; Bonvalot S; Casali PG; Nielsen OS; Delannes M; Litière S; Bonnetain F; Dabakuyo TS; Benjamin RS; Blay JY; Bui BN; Collin F; Delaney TF; Duffaud F; Filleron T; Fiore M; Gelderblom H; George S; Grimer R; Grosclaude P; Gronchi A; Haas R; Hohenberger P; Issels R; Italiano A; Jooste V; Krarup-Hansen A; Le Péchoux C; Mussi C; Oberlin O; Patel S; Piperno-Neumann S; Raut C; Ray-Coquard I; Rutkowski P; Schuetze S; Sleijfer S; Stoeckle E; Van Glabbeke M; Woll P; Gourgou-Bourgade S; Mathoulin-Pélissier S
Ann Oncol; 2015 May; 26(5):865-872. PubMed ID: 25070543
[TBL] [Abstract][Full Text] [Related]
2. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 May; 26(5):873-879. PubMed ID: 25725046
[TBL] [Abstract][Full Text] [Related]
3. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F; Bonsing B; Conroy T; Dousseau A; Glimelius B; Haustermans K; Lacaine F; Van Laethem JL; Aparicio T; Aust D; Bassi C; Berger V; Chamorey E; Chibaudel B; Dahan L; De Gramont A; Delpero JR; Dervenis C; Ducreux M; Gal J; Gerber E; Ghaneh P; Hammel P; Hendlisz A; Jooste V; Labianca R; Latouche A; Lutz M; Macarulla T; Malka D; Mauer M; Mitry E; Neoptolemos J; Pessaux P; Sauvanet A; Tabernero J; Taieb J; van Tienhoven G; Gourgou-Bourgade S; Bellera C; Mathoulin-Pélissier S; Collette L
Eur J Cancer; 2014 Nov; 50(17):2983-93. PubMed ID: 25256896
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar A; Negrier S; Sylvester R; Joniau S; Mulders P; Powles T; Bex A; Bonnetain F; Bossi A; Bracarda S; Bukowski R; Catto J; Choueiri TK; Crabb S; Eisen T; El Demery M; Fitzpatrick J; Flamand V; Goebell PJ; Gravis G; Houédé N; Jacqmin D; Kaplan R; Malavaud B; Massard C; Melichar B; Mourey L; Nathan P; Pasquier D; Porta C; Pouessel D; Quinn D; Ravaud A; Rolland F; Schmidinger M; Tombal B; Tosi D; Vauleon E; Volpe A; Wolter P; Escudier B; Filleron T;
Ann Oncol; 2015 Dec; 26(12):2392-8. PubMed ID: 26371288
[TBL] [Abstract][Full Text] [Related]
6. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
7. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
Le Tourneau C; Michiels S; Gan HK; Siu LL
J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
[TBL] [Abstract][Full Text] [Related]
8. Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document.
Spitzer E; McFadden E; Vranckx P; Garcia-Garcia HM; Seltzer JH; Held C; de Vries T; Menon V; Brown KJ; Soliman OII; Onuma Y; Lopes RD; Stone GW; Cutlip DE; Serruys PW
JACC Cardiovasc Interv; 2019 May; 12(9):805-819. PubMed ID: 31072504
[TBL] [Abstract][Full Text] [Related]
9. Finding a consensus on time-to-event endpoints definitions in marginal zone lymphoma: A Delphi method.
Bommier C; Lambert J; Nowakowski G; Zucca E; Thieblemont C
Hematol Oncol; 2022 Dec; 40(5):1086-1089. PubMed ID: 35299287
[TBL] [Abstract][Full Text] [Related]
10. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
11. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
12. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
13. Consensus Guidelines for the Definition of Time-to-Event End Points in Image-guided Tumor Ablation: Results of the SIO and DATECAN Initiative.
Puijk RS; Ahmed M; Adam A; Arai Y; Arellano R; de Baère T; Bale R; Bellera C; Binkert CA; Brace CL; Breen DJ; Brountzos E; Callstrom MR; Carrafiello G; Chapiro J; de Cobelli F; Coupé VMH; Crocetti L; Denys A; Dupuy DE; Erinjeri JP; Filippiadis D; Gangi A; Gervais DA; Gillams AR; Greene T; Guiu B; Helmberger T; Iezzi R; Kang TW; Kelekis A; Kim HS; Kröncke T; Kwan S; Lee MW; Lee FT; Lee EW; Liang P; Lissenberg-Witte BI; Lu DS; Madoff DC; Mauri G; Meloni MF; Morgan R; Nadolski G; Narayanan G; Newton I; Nikolic B; Orsi F; Pereira PL; Pua U; Rhim H; Ricke J; Rilling W; Salem R; Scheffer HJ; Sofocleous CT; Solbiati LA; Solomon SB; Soulen MC; Sze D; Uberoi R; Vogl TJ; Wang DS; Wood BJ; Goldberg SN; Meijerink MR
Radiology; 2021 Dec; 301(3):533-540. PubMed ID: 34581627
[TBL] [Abstract][Full Text] [Related]
14. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM; Sylvester RJ; Böhle A; Palou J; Lamm DL; Brausi M; Soloway M; Persad R; Buckley R; Colombel M; Witjes JA
J Clin Oncol; 2016 Jun; 34(16):1935-44. PubMed ID: 26811532
[TBL] [Abstract][Full Text] [Related]
15. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
Tolaney SM; Garrett-Mayer E; White J; Blinder VS; Foster JC; Amiri-Kordestani L; Hwang ES; Bliss JM; Rakovitch E; Perlmutter J; Spears PA; Frank E; Tung NM; Elias AD; Cameron D; Denduluri N; Best AF; DiLeo A; Baizer L; Butler LP; Schwartz E; Winer EP; Korde LA
J Clin Oncol; 2021 Aug; 39(24):2720-2731. PubMed ID: 34003702
[TBL] [Abstract][Full Text] [Related]
16. Improving outcome reporting in clinical trial reports and protocols: study protocol for the Instrument for reporting Planned Endpoints in Clinical Trials (InsPECT).
Butcher NJ; Monsour A; Mew EJ; Szatmari P; Pierro A; Kelly LE; Farid-Kapadia M; Chee-A-Tow A; Saeed L; Monga S; Ungar W; Terwee CB; Vohra S; Fergusson D; Askie LM; Williamson PR; Chan AW; Moher D; Offringa M
Trials; 2019 Mar; 20(1):161. PubMed ID: 30841935
[TBL] [Abstract][Full Text] [Related]
17. Alternative clinical end points in rectal cancer--are we getting closer?
Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
[TBL] [Abstract][Full Text] [Related]
18. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
19. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
Punt CJ; Buyse M; Köhne CH; Hohenberger P; Labianca R; Schmoll HJ; Påhlman L; Sobrero A; Douillard JY
J Natl Cancer Inst; 2007 Jul; 99(13):998-1003. PubMed ID: 17596575
[TBL] [Abstract][Full Text] [Related]
20. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]